Incidence, clinical presentation, management, and outcome of acute pericarditis and myopericarditis
| Autor: | Ivo Strebel, Raphael Twerenbold, Gemma Martínez-Nadal, Tobias Zimmermann, Maria Rubini Gimenez, Thomas Nestelberger, Òscar Miró, Beatriz López-Barbeito, Pedro Lopez-Ayala, Christian Puelacher, Dagmar I. Keller, Luca Koechlin, Christian Mueller, Danielle Menosi Gualandro, Jasper Boeddinghaus, Desiree Wussler, Alexandra Prepoudis, Michael Christ, Samyut Shrestha |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Chest Pain Population Critical Care and Intensive Care Medicine Chest pain Pericarditis Acute pericarditis Internal medicine medicine Humans Myocardial infarction education Non-ST Elevated Myocardial Infarction education.field_of_study business.industry Incidence (epidemiology) Incidence Hazard ratio General Medicine Middle Aged medicine.disease Myocarditis Female medicine.symptom Cardiology and Cardiovascular Medicine business Myopericarditis |
| Zdroj: | European heart journal. Acute cardiovascular care. 11(2) |
| ISSN: | 2048-8734 |
| Popis: | Aims Little is known about the epidemiology, clinical presentation, management, and outcome of acute pericarditis and myopericarditis. Methods and results The final diagnoses of acute pericarditis, myopericarditis, and non-ST-segment elevation myocardial infarction (NSTEMI) of patients presenting to seven emergency departments in Switzerland with acute chest pain were centrally adjudicated by two independent cardiologists using all information including serial measurements of high-sensitivity cardiac troponin T. The overall incidence of pericarditis and myopericarditis was estimated relative to the established incidence of NSTEMI. Current management and long-term outcome of both conditions were also assessed. Among 2533 chest pain patients, the incidence of pericarditis, myopericarditis, and NSTEMI were 1.9% (n = 48), 1.1% (n = 29), and 21.6% (n = 548), respectively. Accordingly, the estimated incidence of pericarditis and myopericarditis in Switzerland was 10.1 [95% confidence interval (95% CI) 9.3–10.9] and 6.1 (95% CI 5.6–6.7) cases per 100 000 population per year, respectively, vs. 115.0 (95% CI 112.3–117.6) cases per 100 000 population per year for NSTEMI. Pericarditis (85% male, median age 46 years) and myopericarditis (62% male, median age 56 years) had male predominance, and commonly (50% and 97%, respectively) resulted in hospitalization. No patient with pericarditis or myopericarditis died or had life-threatening arrhythmias within 30 days [incidence 0% (95% CI 0.0–4.8%)]. Compared with NSTEMI, the 2-year all-cause mortality adjusted hazard ratio of pericarditis and myopericarditis was 0.40 (95% CI 0.05–2.96), being 0.59 (95% CI 0.40–0.88) for non-cardiac causes of chest pain. Conclusion Pericarditis and myopericarditis are substantially less common than NSTEMI and have an excellent short- and long-term outcome. Clinical trial registration ClinicalTrial.gov, number NCT00470587, https://clinicaltrials.gov/ct2/show/NCT00470587. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|